ClinicalTrials.gg
CompletedNCT02327013Updated Mar 7, 2018Results posted

Investigating the Effect of Vortioxetine in Adult ADHD Patients

A Phase 2 interventional study of vortioxetine 10 mg tablet and vortioxetine 20 mg tablet in Attention Deficit Hyperactivity Disorder, sponsored by H. Lundbeck A/S. Completed at 15 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
135th of 706
227 · median 70
Started
2014
with 48 others
Phase 2
80 of 807
3 open now
Registered
413th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 135th largest by enrollment of the 706 interventional ones that give a count, is one of 49 that started in 2014, is one of 80 in phase 2, and was the 413th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.

Read the detailed description

The study employed the Sequential Parallel Comparison Design (SPCD), a clinical study design which intend to increase signal detection by using two stages of treatment:

  • Stage 1 - first 6 weeks of the 12-weeks treatment period (Visit 2/Baseline 1 to Visit 5/Week 6)
  • Stage 2 - last 6 weeks of the 12-weeks treatment period (Visit 5/Baseline 2 to Visit 8/Week 12)

In Stage 1, patients were randomized to placebo or vortioxetine 10 or 20mg. Patients on vortioxetine 10 or 20mg/day during Stage 1 remained on the same treatment in Stage 2. Responders to placebo in Stage 1 remained on Placebo in Stage 2. Patients who were placebo non-responders during Stage 1, defined as patients with a \<30% reduction in AISRS total score from Baseline 1, were re-randomized to placebo or vortioxetine 10 or 20mg/day in Stage 2.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is willing and able to attend study appointments within the specified time windows.
  • The patient is an outpatient.
  • The patient is diagnosed with a primary diagnosis of ADHD according to the ™ classification.
  • The patient has an AISRS total score ≥24.
  • The patient has a CGI-S rating ≥4 (moderately ill or worse).

Exclusion criteria

Exclusion Criteria:

  • The patient has previously been treated with vortioxetine.
  • The patient has any current psychiatric disorder (™ criteria), other than ADHD, as assessed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a known first-degree relative with bipolar disorder.
  • The patient suffers from intellectual disability as evaluated by the Wechsler Abbreviated Scale of Intelligence (WASI) II vocabulary and matrix.
  • The patient suffers from organic mental disorders, or mental disorders due to a general medical condition (DSM-5™ criteria).
  • The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates, benzodiazepines, and cannabinoids). If a patient tests positive for opiates due to incidental use of codeine containing medication, as assessed in a clinical interview, the drug screen may be repeated up to three weeks later but the retest result must be available from the central laboratory latest at Visit 2 and has to be negative for this patient to be eligible for enrolment. If a patient tests positive for amphetamines due to his/her ADHD current treatment, as confirmed by a clinical interview, the patient is eligible for enrolment provided this treatment is discontinued two weeks prior to the Baseline Visit.
  • The patient has a history of two prior failed (\<50% improvement in symptoms) adequate trials of ADHD treatment.
  • The patient has any other disorder for which the treatment takes priority over treatment of ADHD or is likely to interfere with study treatment or impair treatment compliance.
  • The patient has a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect central nervous system functioning.
  • The patient has attempted suicide within the last 6 months or is at significant risk of suicide (either in the opinion of the Investigator or defined as a "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behaviour on the Columbia-Suicide Rating Scale (C-SSRS) within the last 12 months).

Other protocol defined inclusion and exclusion criteria do apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    vortioxetine 10 mg tablet

    In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks. In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.

    Drug: vortioxetine 10 mg tablet

  • Experimental
    vortioxetine 20 mg tablet

    In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks. In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.

    Drug: vortioxetine 20 mg tablet

  • Placebo comparator
    Placebo tablet

    In Stage 1, the patients will receive placebo for 6 weeks. In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.

    Other: Placebo tablet

Interventions

  • Oral tablets, once daily

    Also known as: Brintellix®, Lu AA21004, Trintellix®

  • Oral tablets, once daily

    Also known as: Brintellix®, Lu AA21004, Trintellix®

  • OtherPlacebo tablet

    Oral tablets, once daily

06

What researchers measure

Primary outcomes

  1. Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score

    AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index

    The Metacognition Index (MI) is an index score of the BRIEF-A consisting of 5 scales: initiate, working memory, plan/organise, task monitor, and organization of materials. Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  2. Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score

    BRIEF-A is a validated questionnaire composed of 75-item within nine non-overlapping scales: 4 scales in the Behavioral Regulation Index (BRI) (inhibit, shift, emotional control, and self-monitor), and 5 scales in the Metacognition Index (MI) (initiate, working memory, plan/organise, task monitor, and organization of materials). Each item is rated on a 3-point scale with the numeric score of 1 to 3. The BRIEF-A yields an overall score (Global Executive Composite) composed of two index scores, the MI and the BRI. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  3. Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score

    The SDS comprises a series of patient rated scales designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and 3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment. The number of days lost and the number of underproductive days last from work/school due to symptoms are also captured. The total score is calculated as a sum of the 3 visual analogue scales, ranges from 0 to 30. A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  4. Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score

    The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The WLQ Productivity Loss Score is derived from the Global Productivity Index, which is calculated as a weighed sum of the 4 dimensions. Reduction in WLQ Productivity Loss score indicates less work limitation and represents the estimated percentage of productivity loss in the past two weeks due to presenteeism relative to a healthy benchmark sample. WLQ Productivity Loss Score ranges from 0% to 24,9%.

    Time frame: Baseline to Week 6

  5. Change in AISRS Inattention Sub-score

    The AISRS inattentive subscale score consists of 9 items from the AISRS which address inattention. Each item is rated from 0 to 3. The AISRS inattentive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD inattentiveness.

    Time frame: Baseline to Week 6

  6. Change AISRS Hyperactivity/Impulsivity Sub-score

    The AISRS hyperactive/impulsive subscale score consists of 9 items from the AISRS which address hyperactivity and impulsivity. Each item is rated from 0 to 3. The AISRS hyperactive/impulsive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD hyperactivity/impulsivity.

    Time frame: Baseline to Week 6

  7. Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)

    AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.

    Time frame: Baseline to Week 6

  8. Change in Adult ADHD Self-Report Scale (ASRS) Total Score

    The Adult ADHD Self-Report Scale (ASRS) is a patient-rated scale designed to assess the ADHD symptoms in adults based on the diagnostic criteria of DSM-IVTM. The ASRS consist of 18 items, each rated on a 5-point scale from "Never" to "Very Often". The categories "Never" and "Rarely" were combined when calculating the total score to mirror the scoring of the AISRS, with 0 representing "Never"/"Rarely" and 3 representing "Very Often". The Total Score ranges from 0 to 54. A reduction in score indicates less severity of ADHD.

    Time frame: Baseline to Week 6

  9. Change in Clinical Global Impression - Severity of Illness (CGI-S) Score

    The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.

    Time frame: Baseline to Week 6

  10. Clinical Global Impression - Global Improvement (CGI-I) Score

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.

    Time frame: Week 6

  11. Response (Defined as a CGI-I Score of 1 or 2), Stage 1

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.

    Time frame: Week 6

  12. Change in BRIEF-A Using the Behavioural Regulation Index

    The Behavioral Regulation Index (BRI) is an index score of the BRIEF-A and consists of 4 scales: inhibit, shift, emotional control, and self-monitor). Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  13. Change in BRIEF-A Subscales - Inhibit

    The BRIEF-A subscale Inhibit is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  14. Change BRIEF-A Subscales - Initiate

    The BRIEF-A subscale Initiate is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  15. Change in BRIEF-A Subscales - Organization of Materials

    The BRIEF-A subscale Organization of Materials is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  16. Change in BRIEF-A Subscales - Planning/Organize

    The BRIEF-A subscale Planning/Organize is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  17. Change in BRIEF-A Subscales - Shift

    The BRIEF-A subscale Shift is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  18. Change in BRIEF-A Subscales - Self Monitor

    The BRIEF-A subscale Self Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  19. Change in BRIEF-A Subscales - Task Monitor

    The BRIEF-A subscale Task Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  20. Change in BRIEF-A Subscales - Working Memory

    The BRIEF-A subscale Working Memory is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  21. Change in BRIEF-A Subscales - Emotional Control

    The BRIEF-A subscale Emotional Control is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  22. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score

    The PDQ-D is a patient-rated scale designed to assess cognitive impairment/dysfunction adapted for MDD. Each item is rated on a scale from 0 (never) to 4 (almost always). The total score of the 20 items ranges from 0 to 80 with higher scores reflect greater subjective cognitive impairment. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  23. Change in PDQ-D Subscales - Attention and Concentration Sub-score

    The PDQ-D attention/concentration sub-score consists of items 1, 5, 9, 13, and 17 of the PDQ with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

    Time frame: Baseline to Week 6

  24. Change in PDQ-D Sub-scales - Retrospective Memory Sub-score

    The PDQ-D retrospective memory sub-score consists of items 2, 6, 10, 14, and 18 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

    Time frame: Baseline to Week 6

  25. Change in PDQ-D Sub-scales - Prospective Memory Sub-score

    The PDQ-D prospective memory sub-score consists of items 3, 7, 11, 15, and 19 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

    Time frame: Baseline to Week 6

  26. Change in PDQ-D Sub-scales - Planning and Organisation Sub-score

    The PDQ-D planning and organisation sub-score consists of items 4, 8, 12, 16, and 20 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

    Time frame: Baseline to Week 6

  27. Change in SDS Item Scores - Family

    The SDS item family is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  28. Change in SDS Item Scores - Work

    The SDS item work is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  29. Change in SDS Item Scores - Social Life

    The SDS item social life is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  30. Change in SDS Item Scores - Number of Days Lost

    This SDS item captures days lost from school or work (see outcome 4).

    Time frame: Baseline to Week 6

  31. Change in SDS Item Scores - Number of Underproductive Days

    This SDS item captures the number of underproductive days (see outcome 4)

    Time frame: Baseline to Week 6

  32. Change in WLQ Using the Global Productivity Index

    The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The Global Productivity Index is calculated as a weighed sum of the 4 dimensions, and ranges from 0.000 to 0.286. Reduction in score indicates less work limitation.

    Time frame: Baseline to Week 6

  33. Change in WLQ Domain Scores - Limitations Handling Time

    Limitations Handling Time is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

    Time frame: Baseline to Week 6

  34. Change in WLQ Domain Scores - Mental-Interpersonal Work Demands

    Mental-Interpersonal Work Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

    Time frame: Baseline to Week 6

  35. Change in WLQ Domain Scores - Physical Demands

    Physical Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

    Time frame: Baseline to Week 6

  36. Change in WLQ Domain Scores - Output Demands

    Output Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

    Time frame: Baseline to Week 6

  37. Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score

    The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Total score is based on all 29 items and ranges from 29 to 145. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  38. Change in AAQoL Subscales - Life Productivity Sub-score

    The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life productivity subscale is based on 11 items and ranges from 11 to 55. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  39. Change in AAQoL Subscales - Psychological Health Sub-score

    The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Psychological Health subscale is based on 6 items and ranges from 6 to 30. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  40. Change in AAQoL Subscales - Life Outlook Sub-score

    The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life Outlook subscale is based on 7 items and ranges from 7 to 35. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

  41. Change in AAQoL Subscales - Relationships Sub-score

    The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Relationship subscale is based on 5 items and ranges from 5 to 25. A reduction in score indicates less impairment.

    Time frame: Baseline to Week 6

07

Results

Posted Jan 31, 2018
Limitations and caveats
Combined analysis: the overall number of participants analyzed corresponds to the total number of patients in the two stage-wise analyses, where Stage 2 includes patients already included in Stage 1 (patient data not used in the combined analysis).

Participant flow

Participant flow — Overall Study
MilestoneVortioxetine 10mgVortioxetine 20mgPlacebo - PlaceboPlacebo - Vortioxetine 10mgPlacebo - Vortioxetine 20mg
Started4945962116
Completed3629542012
Not completed13164214
Withdrew: Adverse event44301
Withdrew: Lack of efficacy20501
Withdrew: Non-compliance with imp12700
Withdrew: Withdrawal of consent10300
Withdrew: Lost to follow-up24500
Withdrew: Administrative or other reason(s)151111
Withdrew: Protocol violation00301
Withdrew: Withdrawal before treatment21500

Outcome measures

PrimaryChange in ADHD Investigator Symptom Rating Scale (AISRS) Total Score

AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score
units on a scalePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score-12.4 ± 1.25-12.8 ± 1.99-11.6 ± 2.17-4.1 ± 1.92-3.9 ± 1.98-2.9 ± 2.35-8.3 ± 1.1-8.3 ± 1.4-7.3 ± 1.6
Statistical analysis
  • Placebo, Combined vs Vortioxetine 10mg, Combined · weighed z-score · p = 0.9723 · Mean difference (final values): -0.1 · 95% CI -3.6 to 3.5Equally weighed LS z-score, combining results from stagewise MMRM, was compared to standard normal distribution.
  • Placebo, Combined vs Vortioxetine 20mg, Combined · weighed z-score · p = 0.6010 · Mean difference (final values): 1.0 · 95% CI -2.8 to 4.8Equally weighed LS z-score, combining results from stagewise MMRM, was compared to standard normal distribution.
SecondaryInattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index

The Metacognition Index (MI) is an index score of the BRIEF-A consisting of 5 scales: initiate, working memory, plan/organise, task monitor, and organization of materials. Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index
T-scorePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index-10.0 ± 1.26-11.2 ± 1.98-10.2 ± 2.16-3.1 ± 2.28-2.6 ± 2.340.9 ± 2.84-6.5 ± 1.3-6.9 ± 1.5-4.6 ± 1.8
SecondaryCognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score

BRIEF-A is a validated questionnaire composed of 75-item within nine non-overlapping scales: 4 scales in the Behavioral Regulation Index (BRI) (inhibit, shift, emotional control, and self-monitor), and 5 scales in the Metacognition Index (MI) (initiate, working memory, plan/organise, task monitor, and organization of materials). Each item is rated on a 3-point scale with the numeric score of 1 to 3. The BRIEF-A yields an overall score (Global Executive Composite) composed of two index scores, the MI and the BRI. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score
T-scorePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score-9.9 ± 1.22-12.5 ± 1.93-11.4 ± 2.10-3.0 ± 2.24-3.5 ± 2.312.1 ± 2.80-6.5 ± 1.3-8.0 ± 1.5-4.6 ± 1.8
SecondaryOverall Functioning: Change in Sheehan Disability Scale (SDS) Total Score

The SDS comprises a series of patient rated scales designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and 3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment. The number of days lost and the number of underproductive days last from work/school due to symptoms are also captured. The total score is calculated as a sum of the 3 visual analogue scales, ranges from 0 to 30. A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score
units on a scalePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score-5.3 ± 0.74-7.9 ± 1.20-7.4 ± 1.290.6 ± 0.91-0.9 ± 0.95-1.4 ± 1.14-2.4 ± 0.6-4.4 ± 0.8-4.4 ± 0.9
SecondaryProductivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score

The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The WLQ Productivity Loss Score is derived from the Global Productivity Index, which is calculated as a weighed sum of the 4 dimensions. Reduction in WLQ Productivity Loss score indicates less work limitation and represents the estimated percentage of productivity loss in the past two weeks due to presenteeism relative to a healthy benchmark sample. WLQ Productivity Loss Score ranges from 0% to 24,9%.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · percentage of days lost
Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score
percentage of days lostPlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score-2.4 ± 0.54-2.5 ± 0.84-2.4 ± 0.96-0.8 ± 1.02-0.9 ± 0.97-0.7 ± 1.20-1.6 ± 0.6-1.7 ± 0.6-1.5 ± 0.8
SecondaryChange in AISRS Inattention Sub-score

The AISRS inattentive subscale score consists of 9 items from the AISRS which address inattention. Each item is rated from 0 to 3. The AISRS inattentive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD inattentiveness.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in AISRS Inattention Sub-score
units on a scalePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in AISRS Inattention Sub-score-6.5 ± 0.71-6.0 ± 1.14-5.9 ± 1.24-1.9 ± 1.2-2.0 ± 1.21-1.6 ± 1.48-4.2 ± 0.7-4.0 ± 0.8-3.8 ± 1.0
SecondaryChange AISRS Hyperactivity/Impulsivity Sub-score

The AISRS hyperactive/impulsive subscale score consists of 9 items from the AISRS which address hyperactivity and impulsivity. Each item is rated from 0 to 3. The AISRS hyperactive/impulsive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD hyperactivity/impulsivity.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change AISRS Hyperactivity/Impulsivity Sub-score
units on a scalePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1Placebo, Stage 2Vortioxetine 10mg, Stage 2Vortioxetine 20mg, Stage 2Placebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change AISRS Hyperactivity/Impulsivity Sub-score-5.9 ± 0.62-7.0 ± 0.99-5.7 ± 1.08-2.1 ± 0.93-2.0 ± 0.97-1.2 ± 1.15-4.0 ± 0.6-4.5 ± 0.7-3.4 ± 0.8
SecondaryPercentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)

AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.

Time frame:
Baseline to Week 6
Reported as:
Number · percentage of participants
Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)
percentage of participantsPlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)30.927.523.1
SecondaryChange in Adult ADHD Self-Report Scale (ASRS) Total Score

The Adult ADHD Self-Report Scale (ASRS) is a patient-rated scale designed to assess the ADHD symptoms in adults based on the diagnostic criteria of DSM-IVTM. The ASRS consist of 18 items, each rated on a 5-point scale from "Never" to "Very Often". The categories "Never" and "Rarely" were combined when calculating the total score to mirror the scoring of the AISRS, with 0 representing "Never"/"Rarely" and 3 representing "Very Often". The Total Score ranges from 0 to 54. A reduction in score indicates less severity of ADHD.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in Adult ADHD Self-Report Scale (ASRS) Total Score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in Adult ADHD Self-Report Scale (ASRS) Total Score-4.9 ± 1.0-6.5 ± 1.3-3.4 ± 1.4
SecondaryChange in Clinical Global Impression - Severity of Illness (CGI-S) Score

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in Clinical Global Impression - Severity of Illness (CGI-S) Score-0.5 ± 0.1-0.7 ± 0.1-0.6 ± 0.1
SecondaryClinical Global Impression - Global Improvement (CGI-I) Score

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement (CGI-I) Score
units on a scalePlacebo, Stage 1Vortioxetine 10mg, Stage 1Vortioxetine 20mg, Stage 1
Clinical Global Impression - Global Improvement (CGI-I) Score3.01 ± 0.112.93 ± 0.173.15 ± 0.18
SecondaryResponse (Defined as a CGI-I Score of 1 or 2), Stage 1

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.

Time frame:
Week 6
Reported as:
Number · percentages of participants
Response (Defined as a CGI-I Score of 1 or 2), Stage 1
percentages of participantsPlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Response (Defined as a CGI-I Score of 1 or 2), Stage 1431311
SecondaryChange in BRIEF-A Using the Behavioural Regulation Index

The Behavioral Regulation Index (BRI) is an index score of the BRIEF-A and consists of 4 scales: inhibit, shift, emotional control, and self-monitor). Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Using the Behavioural Regulation Index
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Using the Behavioural Regulation Index-5.3 ± 1.1-7.9 ± 1.3-3.9 ± 1.6
SecondaryChange in BRIEF-A Subscales - Inhibit

The BRIEF-A subscale Inhibit is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Inhibit
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Inhibit-5.5 ± 1.4-8.6 ± 1.5-3.2 ± 1.8
SecondaryChange BRIEF-A Subscales - Initiate

The BRIEF-A subscale Initiate is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change BRIEF-A Subscales - Initiate
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change BRIEF-A Subscales - Initiate-6.2 ± 1.4-5.8 ± 1.6-4.2 ± 1.8
SecondaryChange in BRIEF-A Subscales - Organization of Materials

The BRIEF-A subscale Organization of Materials is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Organization of Materials
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Organization of Materials-4.4 ± 1.1-6.3 ± 1.3-3.2 ± 1.5
SecondaryChange in BRIEF-A Subscales - Planning/Organize

The BRIEF-A subscale Planning/Organize is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Planning/Organize
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Planning/Organize-8.2 ± 1.6-8.7 ± 1.8-6.8 ± 2.1
SecondaryChange in BRIEF-A Subscales - Shift

The BRIEF-A subscale Shift is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Shift
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Shift-5.6 ± 1.4-9.1 ± 1.6-3.5 ± 1.9
SecondaryChange in BRIEF-A Subscales - Self Monitor

The BRIEF-A subscale Self Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Self Monitor
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Self Monitor-6.5 ± 1.4-11.0 ± 1.6-4.8 ± 1.8
SecondaryChange in BRIEF-A Subscales - Task Monitor

The BRIEF-A subscale Task Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Task Monitor
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Task Monitor-6.4 ± 1.5-7.8 ± 1.7-4.9 ± 2.0
SecondaryChange in BRIEF-A Subscales - Working Memory

The BRIEF-A subscale Working Memory is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Working Memory
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Working Memory-7.6 ± 1.6-9.9 ± 1.8-3.8 ± 2.1
SecondaryChange in BRIEF-A Subscales - Emotional Control

The BRIEF-A subscale Emotional Control is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · T-score
Change in BRIEF-A Subscales - Emotional Control
T-scorePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in BRIEF-A Subscales - Emotional Control-3.4 ± 1.0-4.8 ± 1.1-3.5 ± 1.4
SecondaryChange in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score

The PDQ-D is a patient-rated scale designed to assess cognitive impairment/dysfunction adapted for MDD. Each item is rated on a scale from 0 (never) to 4 (almost always). The total score of the 20 items ranges from 0 to 80 with higher scores reflect greater subjective cognitive impairment. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score-7.6 ± 1.6-9.3 ± 2.0-6.3 ± 2.2
SecondaryChange in PDQ-D Subscales - Attention and Concentration Sub-score

The PDQ-D attention/concentration sub-score consists of items 1, 5, 9, 13, and 17 of the PDQ with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in PDQ-D Subscales - Attention and Concentration Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in PDQ-D Subscales - Attention and Concentration Sub-score-1.7 ± 0.4-2.3 ± 0.5-1.8 ± 0.6
SecondaryChange in PDQ-D Sub-scales - Retrospective Memory Sub-score

The PDQ-D retrospective memory sub-score consists of items 2, 6, 10, 14, and 18 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in PDQ-D Sub-scales - Retrospective Memory Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in PDQ-D Sub-scales - Retrospective Memory Sub-score-1.8 ± 0.5-2.4 ± 0.6-1.5 ± 0.6
SecondaryChange in PDQ-D Sub-scales - Prospective Memory Sub-score

The PDQ-D prospective memory sub-score consists of items 3, 7, 11, 15, and 19 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in PDQ-D Sub-scales - Prospective Memory Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in PDQ-D Sub-scales - Prospective Memory Sub-score-1.5 ± 0.4-2.3 ± 0.5-0.9 ± 0.6
SecondaryChange in PDQ-D Sub-scales - Planning and Organisation Sub-score

The PDQ-D planning and organisation sub-score consists of items 4, 8, 12, 16, and 20 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in PDQ-D Sub-scales - Planning and Organisation Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in PDQ-D Sub-scales - Planning and Organisation Sub-score-2.4 ± 0.5-2.5 ± 0.6-1.9 ± 0.7
SecondaryChange in SDS Item Scores - Family

The SDS item family is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in SDS Item Scores - Family
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in SDS Item Scores - Family-1.5 ± 0.3-1.8 ± 0.3-1.5 ± 0.4
SecondaryChange in SDS Item Scores - Work

The SDS item work is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in SDS Item Scores - Work
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in SDS Item Scores - Work-1.2 ± 0.3-2.0 ± 0.4-2.1 ± 0.4
SecondaryChange in SDS Item Scores - Social Life

The SDS item social life is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in SDS Item Scores - Social Life
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in SDS Item Scores - Social Life-1.1 ± 0.3-1.7 ± 0.3-1.5 ± 0.4
SecondaryChange in SDS Item Scores - Number of Days Lost

This SDS item captures days lost from school or work (see outcome 4).

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · days
Change in SDS Item Scores - Number of Days Lost
daysPlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in SDS Item Scores - Number of Days Lost-0.3 ± 0.1-0.2 ± 0.1-0.1 ± 0.2
SecondaryChange in SDS Item Scores - Number of Underproductive Days

This SDS item captures the number of underproductive days (see outcome 4)

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · days
Change in SDS Item Scores - Number of Underproductive Days
daysPlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in SDS Item Scores - Number of Underproductive Days-1.2 ± 0.3-1.0 ± 0.3-1.2 ± 0.3
SecondaryChange in WLQ Using the Global Productivity Index

The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The Global Productivity Index is calculated as a weighed sum of the 4 dimensions, and ranges from 0.000 to 0.286. Reduction in score indicates less work limitation.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Index
Change in WLQ Using the Global Productivity Index
IndexPlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in WLQ Using the Global Productivity Index-0.0 ± 0.0-0.0 ± 0.0-0.0 ± 0.0
SecondaryChange in WLQ Domain Scores - Limitations Handling Time

Limitations Handling Time is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in WLQ Domain Scores - Limitations Handling Time
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in WLQ Domain Scores - Limitations Handling Time-5.6 ± 2.7-7.7 ± 3.1-2.2 ± 3.7
SecondaryChange in WLQ Domain Scores - Mental-Interpersonal Work Demands

Mental-Interpersonal Work Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in WLQ Domain Scores - Mental-Interpersonal Work Demands
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in WLQ Domain Scores - Mental-Interpersonal Work Demands-8.4 ± 2.2-8.2 ± 2.6-6.2 ± 2.9
SecondaryChange in WLQ Domain Scores - Physical Demands

Physical Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in WLQ Domain Scores - Physical Demands
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in WLQ Domain Scores - Physical Demands-5.5 ± 2.4-5.0 ± 2.9-4.6 ± 3.2
SecondaryChange in WLQ Domain Scores - Output Demands

Output Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in WLQ Domain Scores - Output Demands
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in WLQ Domain Scores - Output Demands-8.9 ± 3.1-7.1 ± 3.5-7.2 ± 4.0
SecondaryChange in Adult ADHD Quality of Life Measure (AAQoL) Total Score

The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Total score is based on all 29 items and ranges from 29 to 145. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score7.7 ± 1.79.1 ± 2.15.4 ± 2.3
SecondaryChange in AAQoL Subscales - Life Productivity Sub-score

The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life productivity subscale is based on 11 items and ranges from 11 to 55. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in AAQoL Subscales - Life Productivity Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in AAQoL Subscales - Life Productivity Sub-score10.9 ± 2.411.6 ± 2.86.4 ± 3.1
SecondaryChange in AAQoL Subscales - Psychological Health Sub-score

The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Psychological Health subscale is based on 6 items and ranges from 6 to 30. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in AAQoL Subscales - Psychological Health Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in AAQoL Subscales - Psychological Health Sub-score6.7 ± 2.210.3 ± 2.55.7 ± 2.7
SecondaryChange in AAQoL Subscales - Life Outlook Sub-score

The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life Outlook subscale is based on 7 items and ranges from 7 to 35. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in AAQoL Subscales - Life Outlook Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in AAQoL Subscales - Life Outlook Sub-score3.7 ± 1.35.0 ± 1.73.0 ± 1.8
SecondaryChange in AAQoL Subscales - Relationships Sub-score

The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Relationship subscale is based on 5 items and ranges from 5 to 25. A reduction in score indicates less impairment.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Change in AAQoL Subscales - Relationships Sub-score
units on a scalePlacebo, CombinedVortioxetine 10mg, CombinedVortioxetine 20mg, Combined
Change in AAQoL Subscales - Relationships Sub-score7.4 ± 2.18.1 ± 2.56.0 ± 2.7

Adverse events

Collected over Baseline to end of study (16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Placebo0/91 (0%)1/91 (1.1%)39/91 (42.9%)
Vortioxetine 10mg0/68 (0%)1/68 (1.5%)34/68 (50%)
Vortioxetine 20mg0/60 (0%)0/60 (0%)36/60 (60%)
Most frequent serious events
Most frequent serious events
EventPlacebo-PlaceboVortioxetine 10mgVortioxetine 20mg
Suicidal ideationPsychiatric disorders0/911/680/60
ConcussionInjury, poisoning and procedural complications1/910/680/60
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo-PlaceboVortioxetine 10mgVortioxetine 20mg
NauseaGastrointestinal disorders3/9115/6818/60
HeadacheNervous system disorders17/9110/6810/60
FatigueGeneral disorders10/917/6811/60
InsomniaPsychiatric disorders9/914/685/60
DiarrhoeaGastrointestinal disorders3/914/685/60
Weight increasedInvestigations2/915/683/60
NasopharyngitisInfections and infestations4/912/684/60
Abdominal pain upperGastrointestinal disorders2/914/680/60
VomitingGastrointestinal disorders1/914/683/60
DizzinessNervous system disorders4/914/682/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo (Stage 1)Vortioxetine 10mg (Stage 1)Vortioxetine 20mg (Stage 1)Total
Mean37.1 ± 10.335.8 ± 9.637.2 ± 10.436.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Stage 1)Vortioxetine 10mg (Stage 1)Vortioxetine 20mg (Stage 1)Total
Female662419109
Male622325110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Stage 1)Vortioxetine 10mg (Stage 1)Vortioxetine 20mg (Stage 1)Total
American Indian or Alaska Native0000
Asian84113
Native Hawaiian or Other Pacific Islander2103
Black or African American153826
White973731165
More than one race0000
Unknown or Not Reported62412
08

Study locations

15 sites
  • US015
    Beverly Hills, California, United States
  • US002
    Garden Grove, California, United States
  • US004
    National City, California, United States
  • US013
    Bradenton, Florida, United States
  • US006
    Gainesville, Florida, United States
  • US010
    Alpharetta, Georgia, United States
  • US014
    Libertyville, Illinois, United States
  • US011
    Baltimore, Maryland, United States
  • US009
    Boston, Massachusetts, United States
  • US016
    Las Vegas, Nevada, United States
  • US005
    New York, New York, United States
  • US008
    New York, New York, United States
  • US001
    Austin, Texas, United States
  • US007
    Herndon, Virginia, United States
  • US003
    Bellevue, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2014
First posted
Dec 30, 2014
Start
Dec 2014
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Jan 31, 2018
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02327013
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 30, 2014
Start date
Dec 2014
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Jan 31, 2018
Last update
Mar 7, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion